Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-272284
Filing Date
2025-11-07
Accepted
2025-11-07 16:01:45
Documents
124
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 20-F d908386d20f.htm   iXBRL 20-F 3333962
2 EX-4.22 d908386dex422.htm EX-4.22 109300
3 EX-4.23 d908386dex423.htm EX-4.23 123958
4 EX-12.1 d908386dex121.htm EX-12.1 10431
5 EX-12.2 d908386dex122.htm EX-12.2 10383
6 EX-13.1 d908386dex131.htm EX-13.1 6003
7 EX-15.1 d908386dex151.htm EX-15.1 3681
9 GRAPHIC g908386g1107173505030.jpg GRAPHIC 2153
  Complete submission text file 0001193125-25-272284.txt   15110069

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA kzia-20250630.xsd EX-101.SCH 2118449
127 EXTRACTED XBRL INSTANCE DOCUMENT d908386d20f_htm.xml XML 3354242
Mailing Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW Australia 2000
Business Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW Australia 2000 01161298780088
KAZIA THERAPEUTICS LTD (Filer) CIK: 0001075880 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 0630
Type: 20-F | Act: 34 | File No.: 000-29962 | Film No.: 251462476
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)